Johnson & Johnson Release: Adult Patients With Schizophrenia In Singapore To Benefit From The First Three-Monthly Long-Acting Treatment

Published: Oct 10, 2017

- First and only treatment administered four times a year allows schizophrenia patients to focus on other aspects of their lives and rehabilitation plan

- Proven to encourage treatment adherence and reduce risk of relapse[1], [2]

SINGAPORE, 10th OCTOBER 2017 – Johnson & Johnson (J&J) today announced the launch of its three-monthly long-acting treatment for schizophrenia in Singapore. It is the first and only schizophrenia medication to be administered four times a year, providing the longest dosing interval available to patients.

Schizophrenia is a complex and chronic brain disorder in which symptoms can be severe and disabling and can affect all aspects of a person’s daily life. Symptoms include delusions, hallucinations and loss of emotional and psychological functions[3]. Schizophrenia is the ninth leading cause of disability in Singapore (2.7% of total disability-adjusted life-years)[4]. The condition can shorten patients’ lives by as much as 28.5 years[5].

“While the condition is treatable, a major challenge is the high levels of nonadherence in medication taking which affects about one third of patients every year[6],” said Dr Calvin Fones, Consultant Psychiatrist, Gleneagles Medical Centre.

“Nonadherence could lead to relapses, which might in turn, result in grey matter density loss across the course of the illness in schizophrenia. This appears to be related to an increased number of psychotic episodes experienced by a patient, which could result in possible loss of brain functioning as more relapses are experienced[7]. This leads to patient and health services costs, as each relapse can result in reduced response to treatment, putting continued symptom control even further out of reach” Dr Fones added.

Long-acting injectables, such as the new three-month paliperidone palmitate formulation, have been shown to reduce the risk of nonadherence and relapse1,2. The three-month paliperidone palmitate was approved by the Health Sciences Authority of Singapore in March 2017, and is used as a maintenance pharmacotherapy for adult patients with schizophrenia who have been stabilised with the one-month paliperidone palmitate injectable for at least four months. The one-month paliperidone palmitate was approved in Singapore as the first once-monthly atypical long-acting injection to treat schizophrenia.

“A holistic and multidisciplinary programme, including medication, psychosocial intervention, community support and rehabilitation therapy, improves the management of schizophrenia and patient outcomes,” Dr Fones said.

“This first-of-its kind treatment offers patients a new dosing schedule, which can potentially address nonadherence and relapse. Along with social and family support, this treatment approach can provide patients with greater independence and allow them to focus on other aspects of their rehabilitation plan” said Dr Alessandra Baldini, Medical Affairs Director, ONE Johnson & Johnson Singapore.

In a phase 3, multi-centre, long-term maintenance trial, 93% percentage of patients previously adequately stabilized with one-month paliperidone palmitate injectable for at least 4 months and who were subsequently treated with three-month paliperidone palmitate (trade name INVEGA TRINZA™) did not experience a significant return of schizophrenia symptoms. The results of the phase 3 study were published in JAMA Psychiatry, a peer-reviewed medical journal published by the American Medical Association[8].


Media contacts

Pia Tyagi
Johnson & Johnson Southeast Asia
Stephanie Tan/
Jessica Bridges/Clarinda Ng
Spurwing Communications
Tel: +65 6340 7287

About Schizophrenia

Schizophrenia is the ninth leading cause of disability in Singapore (2.7% of total disability-adjusted life-years). It often begins in early adulthood, just as individuals are establishing their independence. The course of schizophrenia is varied, frequently involving periodic relapses of the disease with sometimes incomplete response to treatment. Each relapse can result in reduced response to treatment, putting continued symptom control even further out of reach3,4.

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Back to news